{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:28:07Z","timestamp":1786998487820,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ygyno.2024.03.006","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T12:39:44Z","timestamp":1713443984000},"page":"104-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer"],"prefix":"10.1016","volume":"186","author":[{"given":"Sarah","family":"Ehmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Iasonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel N.","family":"Grisham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Tew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin E.","family":"O'Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Long Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.ygyno.2024.03.006_bb0005","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2024.03.006_bb0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2024.03.006_bb0015","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2024.03.006_bb0020","first-page":"98","article-title":"The role of maintenance therapy in ovarian cancer","volume":"18","author":"Oza","year":"2020","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2024.03.006_bb0025","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.ygyno.2024.03.006_bb0030","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ygyno.2024.03.006_bb0035","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"issue":"10106","key":"10.1016\/j.ygyno.2024.03.006_bb0040","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ygyno.2024.03.006_bb0045","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"30","key":"10.1016\/j.ygyno.2024.03.006_bb0050","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.006_bb0055","author":"Society of Gynecologic Oncology"},{"issue":"9","key":"10.1016\/j.ygyno.2024.03.006_bb0060","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2024.03.006_bb0065","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.03.006_bb0070","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2017.02.010","article-title":"A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer","volume":"145","author":"Cowan","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.03.006_bb0075","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ygyno.2021.07.026","article-title":"Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer","volume":"163","author":"Moss","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.03.006_bb0080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2024.03.006_bb0085","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2024.03.006_bb0090","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/ijgc-2022-003435","article-title":"Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups","volume":"32","author":"Schettino","year":"2022","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T17:59:39Z","timestamp":1727805579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824001513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":18,"alternative-id":["S0090825824001513"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.03.006","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}